Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Randomized Comparison of Bioheart Sirolimus-Eluting Bioresorbable Scaffold and Everolimus-Eluting Stents: The BIOHEART-II Trial.
JACC Cardiovasc Interv
January 2025
Department of Cardiology, Fu Wai Hospital, National Center for Cardiovascular Diseases of China, Beijing, China. Electronic address:
Background: First-generation bioresorbable scaffolds (BRS) increased risks of stent thrombosis and adverse events. The Bioheart scaffold is a new poly-L-lactic acid-based BRS.
Objectives: This study sought to evaluate the efficacy and safety of the BRS in patients with coronary artery disease.
Early and Late Outcomes With the Absorb Bioresorbable Vascular Scaffold: Final Report From the ABSORB Clinical Trial Program.
JACC Cardiovasc Interv
January 2025
Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address:
Background: The risk-benefit ratio of the Absorb bioresorbable vascular scaffold (BVS) may vary before and after 3 years, the time point of complete bioresorption of the poly-L-lactic acid scaffold.
Objectives: The aim of this study was to determine the time-varying outcomes of the Absorb BVS compared with cobalt-chromium everolimus-eluting stents (EES) from a large individual-patient-data pooled analysis of randomized trials.
Methods: The individual patient data from 5 trials that randomized 5,988 patients undergoing percutaneous coronary intervention to the Absorb BVS vs EES with 5-year follow-up were pooled.
Occlusion of Dorsalis Pedis Artery in an Athlete.
Intern Med
January 2025
Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
A 17-year-old Japanese boy was admitted to our hospital with intermittent claudication. He belonged to a weightlifting team at a high school. He had occasionally dropped lightweight lifting weights on his right foot.
View Article and Find Full Text PDFFRED-EPI study: Safety and efficacy of FRED/FRED Jr aneurysm treatment in current clinical practice.
J Neuroradiol
January 2025
Departments of Neuroradiology, HCL, Lyon, France.
Objective: Flow diversion is increasingly used as an endovascular treatment for intracranial aneurysms. FRED-EPI is a prospective, multicenter, French study, conducted to analyze the safety and efficacy of aneurysm treatment with FRED/FRED Jr (Microvention, AlisoViejo, CA, USA) in current clinical practice.
Patients And Methods: Patients with intracranial aneurysms treated with FRED and FRED Jr who agreed to participate were prospectively and consecutively included in all French centers using these devices.
Safety and Efficacy of Tranexamic Acid in General Surgery.
JAMA Surg
January 2025
Population Health Research Institute, Hamilton, Ontario, Canada.
Importance: Perioperative bleeding is common in general surgery. The POISE-3 (Perioperative Ischemic Evaluation-3) trial demonstrated efficacy of prophylactic tranexamic acid (TXA) compared with placebo in preventing major bleeding without increasing vascular outcomes in noncardiac surgery.
Objective: To determine the safety and efficacy of prophylactic TXA, specifically in general surgery.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!